Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yoshihiro Matsumoto, Dialysis Outcomes Heart Failure Aldactone Study Group
ClinicalTrials.gov Identifier:
NCT01687699
First received: September 12, 2012
Last updated: September 14, 2012
Last verified: September 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)